Drug intelligence / Profile preview

isosorbide mononitrate + cilostazol

Development stage: Unknown
Lead developer: University of Edinburgh
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of isosorbide mononitrate (ISMN), a nitric oxide donor, and cilostazol, a phosphodiesterase-3 inhibitor. This combination targets cerebrovascular dysfunction through complementary pathways, with ISMN augmenting the NO-cyclic guanosine monophosphate pathway and cilostazol enhancing the prostacyclin-cyclic adenosine monophosphate pathway. Clinical trials have shown promise in reducing adverse outcomes after lacunar ischemic stroke, including recurrent stroke, cognitive impairment, and dependence.

Other names: ISMN + cilostazolCilostazol and Isosorbide Mononitrate

Targets

PDE3sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on isosorbide mononitrate + cilostazol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on isosorbide mononitrate + cilostazol.

Explore the full profile